Risankizumab (IL-23i) KEEPsAKE 1 and 2 (phase 3) studies for PsA treatment
⬆️ACR20 response compared to pbo
⬆️secondary endpoints
⭐️no new safety signals
Abs#453
#ACR21 #ACRBest @RheumNow
https://t.co/7bwvIPMz38 https://t.co/TJaSqwipa5
Links:
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Int…
https://bit.ly/3bNPV4C
06-11-2021